(Q24199096)

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

Pharmacodynamic interest of ceftazidime continuous infusion vs intermittent bolus administration in patients with severe nosocomial pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

Treatment of gram-negative bacillary septicemia with cefoperazone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

Optimizing ceftazidime pharmacodynamics in patients with acute exacerbation of severe chronic bronchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

Piperacillin penetration into tissue of critically ill patients with sepsis--bolus versus continuous administration?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

Continuous vs. intermittent cefotaxime administration in patients with chronic obstructive pulmonary disease and respiratory tract infections: pharmacokinetics/pharmacodynamics, bacterial susceptibility and clinical efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

Cefazolin bolus and continuous administration for elective cardiac surgery: improved pharmacokinetic and pharmacodynamic parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

Pharmacokinetics of ceftazidime in serum and peritoneal exudate during continuous versus intermittent administration to patients with severe intra-abdominal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam when administered by continuous infusion and intermittent dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

Influence of vancomycin on renal function in critically ill patients after cardiac surgery: continuous versus intermittent infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

Continuous infusion versus intermittent administration of cefepime in patients with Gram-negative bacilli bacteraemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

Comparison of the pharmacodynamics of imipenem in patients with ventilator-associated pneumonia following administration by 2 or 0.5 h infusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

Comment: converting patients from brand-name clozapine to generic clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

Comparison of the pharmacokinetics of piperacillin and sulbactam during intermittent and continuous intravenous infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

Cost-effectiveness of ceftazidime by continuous infusion versus intermittent infusion for nosocomial pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

Treatment of Serratia marcescens meningitis with prolonged infusion of meropenem.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

Serum concentrations of cefuroxime after continuous infusion in coronary bypass graft patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

Continuous-infusion oxacillin for the treatment of burn wound cellulitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

Plasma and peritoneal concentration following continuous infusion of cefotaxime in patients with secondary peritonitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

Continuous infusion versus intermittent administration of meropenem in critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

Population pharmacokinetic analysis of nonlinear behavior of piperacillin during intermittent or continuous infusion in patients with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

High dose vancomycin for osteomyelitis: continuous vs. intermittent infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

A pilot study to determine the feasibility of continuous cefazolin infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

GRADE guidelines: 3. Rating the quality of evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

The Prevalence of ESBLs Producing Klebsiella pneumoniae Isolates in Some Major Hospitals, Iran

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

Continuous versus intermittent intravenous administration of antibacterials with time-dependent action: a systematic review of pharmacokinetic and pharmacodynamic parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

Low cefpirome levels during twice daily dosing in critically ill septic patients: pharmacokinetic modelling calls for more frequent dosing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

Increase of patients co-colonised or co-infected with methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium or extended-spectrum β-lactamase-producing Enterobacteriaceae

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

Better outcomes through continuous infusion of time-dependent antibiotics to critically ill patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

A systematic review on clinical benefits of continuous administration of beta-lactam antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

International Nosocomial Infection Control Consortium (INICC) report, data summary of 36 countries, for 2004-2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

Does prolonged β-lactam infusions improve clinical outcomes compared to intermittent infusions? A meta-analysis and systematic review of randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

Comparative stability studies of antipseudomonal beta-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

Continuous versus intermittent infusions of antibiotics for the treatment of severe acute infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

Continuous infusion ceftazidime in intensive care: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

7 January 2021

Intermittent and continuous ceftazidime infusion for critically ill trauma patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

7 January 2021

Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

7 January 2021

Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

7 January 2021

Cost comparison of single daily i.v. doses of ceftriaxone versus continuous infusion of cefotaxime

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

7 January 2021

Cost analysis of continuous versus intermittent infusion of piperacillin-tazobactam: a time-motion study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

7 January 2021

Is continuous infusion ceftriaxone better than once-a-day dosing in intensive care? A randomized controlled pilot study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

7 January 2021

The jury is still out on continuous infusion of beta-lactam antibiotics in intensive care patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

7 January 2021

Serum bactericidal activity of ceftazidime: continuous infusion versus intermittent injections.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

7 January 2021

Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

7 January 2021

Comparison of concentrations of sulbactam-ampicillin administered by bolus injections or bolus plus continuous infusion in tissues of patients undergoing colorectal surgery

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

7 January 2021

A pilot study of the efficacy of constant-infusion ceftazidime in the treatment of endobronchial infections in adults with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

7 January 2021

Pharmacoeconomics of continuous versus intermittent infusion of piperacillin-tazobactam for the treatment of complicated intraabdominal infection

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

7 January 2021

Should IV Antibiotics Be Administered by Prolonged Infusion?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

7 January 2021

Cefepime in critically ill patients: continuous infusion vs. an intermittent dosing regimen.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008481.PUB2

7 January 2021